Consistently, the expression of CDKN1C and KIT was lower in cancers, including KIRC, KIRP, and BRCA, while ICAM1, SSX2IP, and TNFSF10 were higher in cancers, including STAD and CESC, opposing the effects of miR-221/222-3p (Figure 5). Here, ICAM1 is linked to cancer.